DAWN Stock Forecast & Price Target

Day One Biopharmaceuticals Inc. reported a total revenue of $131.2 million for the year, with $57.2 million stemming from Ojemda net product sales, showcasing strong financial performance driven by increased prescription volumes and improved gross-to-net revenue. The company anticipates continued growth as prescribers become more familiar with Ojemda's benefits, leading to increasing treatment durations and a rise in new patient additions, particularly as Ojemda establishes itself as the standard of care for second-line therapy. With ongoing enrollment in the FIREFLY-2 trial for tovorafenib and a notable growth in prescription counts reaching 1,647 by year-end 2024, Day One is positioned for a positive outlook, bolstered by high confidence from treatment centers and optimized inventory management.

The financial outlook for Day One Biopharmaceuticals Inc. is negatively impacted by several fundamental factors. The classification of OJEMDA as a pediatric-only therapy has resulted in reduced rebate percentages, leading to a downward revision in gross-to-net impact estimates from 15–18% to 12–15%. Furthermore, substantial net losses reported for FY24, amounting to $95.5 million, along with clinical and regulatory uncertainties regarding DAY101/pimasertib, present significant risks to the company's financial health and future performance.